https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-05-31 / J Clin Oncol 31, 2013 (suppl; abstr e13029)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-05-31 / J Clin Oncol 31, 2013 (suppl; abstr e13029)2013-05-31 00:00:002013-05-31 00:00:00Outcome of an advanced anaplastic astrocytoma patient treated with Newcastle disease viral (NDV) oncolytic therapy.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-05-31 / J Clin Oncol 31, 2013 (suppl; abstr e19018)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-05-31 / J Clin Oncol 31, 2013 (suppl; abstr e19018)2013-05-31 00:00:002013-05-31 00:00:00Impact of dendritic cells combining with cytokine-induced killer cells synergized chemotherapy in patients of advanced non-small cell lung cancer.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-05-30 / Acta Med Iran 2013 May;51(5):284-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-05-30 / Acta Med Iran 2013 May;51(5):284-82013-05-30 00:00:002019-02-15 08:48:37Vaccination of diffuse large B- cell lymphoma patients with antigen-primed dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-05-14 / Cancer Chemother. Pharmacol. 2013 Jul;72(1):139-46
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-05-14 / Cancer Chemother. Pharmacol. 2013 Jul;72(1):139-462013-05-14 00:00:002013-05-14 00:00:00Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-05-01 / Anticancer Res. 2013 May;33(5):2047-56
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-05-01 / Anticancer Res. 2013 May;33(5):2047-562013-05-01 00:00:002019-02-15 08:34:51Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas
